Skip Navigation

European Heart Journal 2003 24(12):1120-1127; doi:10.1016/S0195-668X(03)00209-4
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gullestad, L.
Right arrow Articles by Pernow, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gullestad, L.
Right arrow Articles by Pernow, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Regular Articles

The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris

L. Gullestada, T. Bjurøb, L. Aabergea, T. Apellanda, R. Skårdala, E. Kjekshusa, M. Nordlanderc, B. Åbladc and J. Pernowd,*

a Department of Cardiology Rikshospitalet University Hospital, Oslo, Norway
b Wallenberg Laboratory, Sahlgrens University Hospital, Gothenburg, Sweden
c AstraZeneca R & D, Mölndal, Sweden
d Department of Cardiology, Karolinska Hospital, Stockholm, Sweden

* Correspondence to: John Pernow, MD, PhD, Department of Cardiology, Karolinska Hospital, S-171 76 Stockholm, Sweden. Tel: +46 8 51775876; fax: +46 8 311044
E-mail address: john.pernow{at}ks.se

Received 27 November 2002; revised 21 February 2003; accepted 20 March 2003

Aims Neuropeptide Y (NPY) is a potent vasoconstrictor released during sympathetic activation that may be involved in myocardial ischaemia. We examined the effect of a Y1 receptor antagonist on haemodynamic and ischaemic responses to exercise in patients with coronary artery disease.

Methods and results Eighty-two evaluable male patients were included in a randomized, double blind, two-way crossover study with a low dose (6.7µg/kg/min; n=59)and a high dose (13.3µg/kg/min; n=23) of the Y1 receptor antagonist AR-H040922 given as infusions for 2h or placebo. Myocardial ischaemia during a symptom-limited exercise test was monitored by conventional ST-segment analysis and heart rate (HR)-adjusted ST changes including the ST/HR slope and ST/HR recovery. Administration of the high dose AR-H040922 attenuated systolic blood pressure by 6–11mmHg (p<0.05) during and after exercise without affecting HR. None of the two doses of AR-H040922 influenced any of the ischaemic parameters or duration of exercise, however. The maximal increase in NPY was higher during AR-H040922 (p<0.05) compared with placebo.

Conclusions Selective NPY Y1 receptor blockade attenuates the increase in blood pressure during exercise indicating a role for endogenous NPY in blood pressure regulation. Despite this effect, the Y1 receptor antagonist did not influence exercise-induced ischaemic parameters in patients with coronary artery disease.

Key Words: Coronary artery disease • exercise testing • myocardial ischaemia • peptides


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.